Dong-A Hwa Sung Co.,Ltd. (KOSDAQ:041930)
6,860.00
-80.00 (-1.15%)
At close: Feb 27, 2026
Dong-A Hwa Sung Revenue
Dong-A Hwa Sung had revenue of 101.75B KRW in the quarter ending September 30, 2025, with 4.27% growth. This brings the company's revenue in the last twelve months to 405.21B, up 7.87% year-over-year. In the year 2024, Dong-A Hwa Sung had annual revenue of 383.21B with 3.93% growth.
Revenue (ttm)
405.21B
Revenue Growth
+7.87%
P/S Ratio
0.25
Revenue / Employee
1.39B
Employees
291
Market Cap
100.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 383.21B | 14.49B | 3.93% |
| Dec 31, 2023 | 368.72B | 19.08B | 5.46% |
| Dec 31, 2022 | 349.64B | 60.88B | 21.08% |
| Dec 31, 2021 | 288.76B | 26.99B | 10.31% |
| Dec 31, 2020 | 261.77B | -26.75B | -9.27% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NVH Korea | 1.64T |
| SGC E&C | 1.37T |
| Theragen Etex | 268.13B |
| CTCBIO | 132.76B |
| APS Inc. | 130.86B |
| Finger | 87.95B |
| Sam-A Pharm. | 76.66B |
| Korea Business News | 73.44B |